Nanobiotix S.A. (NBTX) Research
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
Market snapshot
- Symbol
- NBTX
- Price
- $36.27
- Day change
- +0.55%
- Market cap
- $1.5B
- P/E ratio
- -58.78x
- 52-week range
- 4.308-57.14
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 3 months
- Analyst price target
- $38.00
Recent news
- How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer
Nanobiotix wants to fundamentally change a century-old mainstay in battling cancer. The top-notch biotech stock is flying.
- Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
The stock's movement follows a statement clarifying that there is no ongoing process or assessment for a takeover, which has helped to stabilize investor sentiment as broader markets are experiencing gains.
Peer companies
Open Nanobiotix S.A. (NBTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.